After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

The company wants to create two focused companies dedicated to driving current and future value in their respective ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics. The two companies will work together to ensure the production of Viking’s GLP ...

Drugs like Ozempic have a positive impact on weight loss, though only for a short period, with long-term health implications ...

Even as Singapore attempts to revive its stock market, and despite challenging exits, private equity continues to flourish ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...